Clinical trials: Advanced Solid Tumor (Phase 1), open to volunteers
Colorectal Cancer, Advanced/Metastatic Solid Tumor
This is a Phase 1/1b Study to Evaluate the Safety and Preliminary Antitumor Activity of LTZ-232 in Participants With Advanced/Metastatic Colorectal Cancer and Other Solid Tumors
This is a first-in-human, Phase 1, multi-center, open-label study to characterize the safety, pharmacokinetics, pharmacodynamics, and preliminary anti tumor activity of LTZ-232 as monotherapy in adult participants with…
- Conditions
- Colorectal Cancer, Advanced/Metastatic Solid Tumor, Solid Tumor (Phase I), EPCAM
- Trial name
- NCT07878988
- Testing
- LTZ-232
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- LTZ Therapeutics, Inc.
Solid Tumors (Phase 1), HNSCC
MTX-531-001 Phase 1 Study in Advanced Solid Tumors
This is a first-in-human, Phase 1, open-label study evaluating MTX-531, an investigational dual EGFR/PI3K inhibitor, in adults with advanced solid tumors.
- Conditions
- Solid Tumors (Phase 1), HNSCC, Endometrial Cancer, Her2-negative Metastatic Breast Cancer
- Trial name
- NCT07874880
- Testing
- MTX-531
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- MEKanistic Therapeutics, Inc.
Advanced Solid Cancer, Advanced Solid Tumor (Phase 1)
A Phase 1 Study of APX-343A as Monotherapy or in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
This is a Phase 1, open-label, dose-escalation study to assess the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of APX-343A monotherapy (Part A) and in combination with pembrolizumab (Part B) in subjects…
- Trial name
- NCT07123415
- Testing
- APX-343A, Pembrolizumab
- Where
- 3 sites in South Korea
- Volunteers
- 110 people
- Sponsor
- Aptabio Therapeutics, Inc.
Advanced Solid Tumor (Phase 1)
A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of HSK46256 in Patients With Advanced Solid Tumors
This is a Phase 1, open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of HSK46256 tablets, a selective PARP1 inhibitor, in patients with advanced solid tumors.
- Trial name
- NCT07695142
- Testing
- HSK46256
- Where
- China
- Volunteers
- 275 people
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
Advanced Solid Tumor (Phase 1)
EP102 Safety and Efficacy in METTL3 Modulation in Advanced Solid Tumors
This the first-in-human (FIH) study for the Investigational Medicinal Product (IMP) EP102, is designed to explore the maximum tolerated dose (MTD), the overall safety profile, its pharmacokinetic (PK) / pharmacodynamic (PD)…
- Trial name
- NCT07163325
- Testing
- EP102
- Where
- 11 sites in Belgium, Czechia and 2 more
- Volunteers
- 48 people
- Sponsor
- Epics Therapeutics
Advanced Solid Tumor (Phase 1)
An Initial Evaluation of AN8025 in Solid Tumors
The goal of this clinical trial is to determine the appropriate dose of AN8025 for use in the treatment of advanced solid tumors. This study will be conducted in in adults >18 years of age. The main questions to answer: 1.
- Trial name
- NCT07639047
- Testing
- AN8025 is a multifunctional antibody fusion protein
- Where
- Australia
- Volunteers
- 91 people
- Sponsor
- Adlai Nortye Biopharma Co., Ltd.
Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma
A Phase I Study of JLM019 Injection
This is a multicenter, single-arm, open-label, dose escalation phase (Part A) and dose expansion (Part B) study to evaluate the safety and tolerability of JLM019 Injection in patients with advanced malignancies.
- Conditions
- Advanced Solid Tumor (Phase 1), Hodgkin Lymphoma, Non-Hodgkin Lymphoma
- Trial name
- JLM019 (NCT07623850)
- Testing
- JLM019 Injection
- Where
- China
- Volunteers
- 115 people
- Sponsor
- Jecho Biopharmaceuticals Co., Ltd.
Advanced Solid Tumor (Phase 1)
Evaluation of T320, an Anti-Tissue Factor Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors
This is a first-in-human, non-randomized, open-label, multi-center, phase I study in patients with advanced solid tumor to evaluate the safety and tolerability, PK, immunogenicity, and preliminary anti-tumour activity of T320.
- Trial name
- NCT07434609
- Testing
- T320 for Injection
- Volunteers
- 150 people
- Sponsor
- Nanolattix Biotechnology Co., Ltd.
Advanced Solid Tumors (Phase 1)
Safety and Tolerability Evaluation of CEL001 Injection in Advanced Solid Tumors
This study is the first human, open label, dose escalation, and expansion phase I clinical trial aimed at evaluating the safety, tolerability, preliminary efficacy, pharmacokinetic characteristics, biomarker changes, and…
- Trial name
- NCT07259889
- Testing
- NK cell preparation
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Guangzhou Xiling Biotechnology Co., Ltd.
Advanced Solid Tumors (Phase 1)
A Phase I Study OfLNF2007 Monotherapy in Patients with Advanced Solid Tumors
A non-randomized, open-ended, phase I dose-escalation and dose-expansion study was designed to evaluate the safety, tolerability, antitumor efficacy, PK and immunogenic characteristics of LNF2007 in patients with advanced solid…
- Trial name
- NCT06752447
- Testing
- LNF2007
- Volunteers
- 94 people
- Sponsor
- Shandong New Time Pharmaceutical Co., LTD
Solid Tumors (Phase 1), Mesothelioma
Phase 1 Dose Escalation and Expansion to Evaluate AROG4-01 in Patients With Advanced Solid Tumors
The goal of this clinical trial is to learn if drug AROG4-01 is safe in patients with solid tumors who have no available treatment alternative. Different doses will be tested in order to identify the most suitable one.
- Conditions
- Solid Tumors (Phase 1), Mesothelioma, Colorectal Carcinoma, Ovarian Cancer
- Trial name
- AROG4-01-01 (NCT06652529)
- Testing
- AROG4-01
- Volunteers
- 35 people
- Sponsor
- Aromics Therapeutics